Testing naltrexone and propranolol with melanoma immunotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 study tests whether adding naltrexone and propranolol to standard immunotherapy (ipilimumab plus nivolumab) can improve outcomes for people with advanced melanoma. It also aims to better understand safety and how the combination works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent.
- You have stage III or IV melanoma that cannot be fully removed by surgery.
- You can start standard treatment with ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg).
- You are well enough for treatment (ECOG performance status 0 to 1) and expected to live at least 6 months.
- You can provide a tumor biopsy (new or stored archived tissue) for study testing.
- Your blood and organ tests are in a safe range (including white blood cells, platelets, liver tests, and bilirubin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.